d, 1H, J= 8 Hz), (7.94, d, 1H, J= 8 Hz), (7.88, t, 1H, J= 8 Hz), (7.71, t, 2H, J= 7-8 Hz), (7.41, d, 1H, J= 8 Hz), (4.19, s, 2H), (3.72, s, 3H). (25) N-(3,5-dichlorophenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)- acetamide. 1 H NMR (DMSO-d6, 400 MHz): (10.79, s, 1H), (8.37, d, 1H, J= 8 Hz), (8.01, d, 2H, J= 7 Hz), (7.94, 1H), (7.71, s, 2H), (7.36, s, 1H), (4.19, s, 2H), (3.78, s, 3H). (26) N-(3,4,5-trichlorophenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1- yl)acetamide. 1 H NMR (DMSO-d6, 400 MHz): (10.96, s, 1H), (8.27, d, 1H, J= 8 Hz), (8.02, 2H), (7.94, 2H), (4.20, s, 2H), (3.79, s, 3H). (27) N-(3,4,5-trifluorophenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1- yl)aceta-mide. 1 H NMR (DMSO-d6, 400 MHz): (10.71, s, 1H), (8.26, d, 1H, J= 8 Hz), (7.90, s, 2H), (7.83, 1H), (7.45, 2H), (4.07, s, 2H), (3.67, s, 3H). (28) N-(4-bromo-3-chlorophenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin- 1-yl)-acetamide. 1 H NMR (DMSO-d6, 400 MHz): (10.67, s, 1H), (8.20, d, 1H, J= 8 Hz), (7.97, d, 1H, J= 7 Hz), (7.94, d, 2H, J= 8 Hz), (7.87, t, 1H, J= 7 Hz), (7.70, d, 1H, J= 8 Hz), (7.41, d, 1H, J= 8 Hz), (4.12, s, 2H), (3.72, s, 3H). (29) N-(4-bromo-3-(trifluoromethyl)phenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide. 1 H NMR (DMSO-d6, 400 MHz): (10.83, s, 1H), (8.21, d, 1H, J= 8 Hz), (8.19, d, 1H, J= 7 Hz), (7.96, q, 2H, J= 8 Hz), (7.88, t, 1H, J= 7-8 Hz), (7.84, d, 1H, J= 8 Hz), (7.75, d, 1H, J= 12 Hz), (4.15, s, 2H), (2.74, s, 3H). (30) N-(4-chloro-3-(trifluoromethyl)phenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide. 1 H NMR (DMSO-d6, 400 MHz): (10.84, s, 1H), (8.31, d, 26
1H, J= 7 Hz), (8.17, d, 1H, J= 9 Hz), (7.95, q, 2H, J= 8 Hz), (7.88, t, 1H, J= 7 Hz), (7.82, d, 1H, J= 8 Hz), (7.68, d, 1H, J= 8 Hz), (4.06, s, 2H), (3.72, s, 3H). (31) N-(4-cyano-3-(trifluoromethyl)phenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide. 1 H NMR (DMSO-d6, 400 MHz): (11.17, s, 1H), (8.31, d, 1H, J= 8 Hz), (8.27, s, 1H), (8.11, d, 1H, J= 8 Hz), (7.95, q, 3H, J= 7-8 Hz), (7.88, t, 1H, J= 8 Hz), (4.20, s, 2H), (3.72, s, 3H). (32) N-(3-chloro-4-cyanophenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1- yl)acetamide. 1 H NMR (DMSO-d6, 400 MHz): (10.80, s, 1H), (8.26, d, 1H, J= 8 Hz), (8.14, s, 1H), (7.90, q, 2H, J= 8 Hz), (7.82, t, 1H, J= 8 Hz), (7.77, d, 1H, J= 8 Hz), (7.63, d, 1H, J= 8 Hz), (4.09, s, 2H), (3.67, s, 3H). (33) N-(4-fluoro-3-(trifluoromethyl)phenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthal-azin-1-yl)acetamide. 1 H NMR (DMSO-d6, 400 MHz): (10.74, s, 1H), (8.30, d, 1H, J= 8 Hz), (8.09, d, 1H, J= 8 Hz), (7.97, d, 1H, J= 8 Hz), (7.93, d, 1H, J= 8 Hz), (7.87, t, 1H, J= 8 Hz), (7.82, t, 1H, J= 7-8 Hz), (7.49, t, 1H, J= 10 Hz), (4.13, s, 2H), (3.72, s, 3H). (34) N-(4-methoxy-3-(trifluoromethyl)phenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide. 1 H NMR (DMSO-d6, 400 MHz): (10.57, s, 1H), (8.34, d, 1H, J= 8 Hz), (8.00, q, 3H, J= 7-8 Hz), (7.91, t, 1H, J= 7-8 Hz), (7.81, d, 1H, J= 8 Hz), (7.28, d, 1H, J= 8 Hz), (4.14, s, 2H), (3.89, s, 3H), (3.77, s, 3H). (35) N-(4-amino-3-(trifluoromethyl)phenyl)-2-(3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetamide. 1 H NMR (DMSO-d6, 400 MHz): (10.20, s, 1H), (8.29, d, 1H, J= 8 Hz), (7.95, q, 2H, J= 7-8 Hz), (7.86, t, 1H, J= 7-8 Hz), (7.69, s, 1H), (7.39, d, 1H, J= 8 Hz), (6.78, d, 1H, J= 8 Hz), (5.40, s, 2H), (4.09, s, 2H), (3.71, s, 3H). 27
- Page 1 and 2: Synthesis and Biological Evaluation
- Page 3 and 4: inducing enzyme inhibition. Further
- Page 5 and 6: List of Tables Table I. Table II. I
- Page 7 and 8: Introduction Outbreaks worldwide ha
- Page 9 and 10: Compound 7 and its analogs were pre
- Page 11 and 12: D21 9 Me 2-OMePh >5000 ND D23 10 Me
- Page 13 and 14: D35 51 Me thiazolyl) 2-(5-Me(1,3,4-
- Page 15 and 16: Figure III. Intramolecular interact
- Page 17 and 18: Figure IV. Ball-and-stick model of
- Page 19 and 20: methoxy group. We believe that this
- Page 21 and 22: enzofuran series of inhibitors. How
- Page 23 and 24: Trends in potency seemed to increas
- Page 25 and 26: Conclusion We have hypothesized, ap
- Page 27 and 28: chemical shift values are also repo
- Page 29 and 30: General procedure for the synthesis
- Page 31: (15) N-(4-bromophenyl)-2-(3-methyl-
- Page 35 and 36: (7.95, q, 2H, J= 7-8 Hz), (7.87, t,
- Page 37 and 38: 1H, J= 8 Hz), (7.31, d, 1H, J= 8 Hz
- Page 39: Bibliography 1. Huang, D.R.; White,